Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
Cancer Medicine2018Vol. 8(1), pp. 137–146
Citations Over TimeTop 1% of 2018 papers
Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, Kunihiko Tsuji, Kazuto Tajiri, Masashi Hirooka, Noritomo Shimada, Hiroshi Shibata, Toru Ishikawa, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Akemi Tsutsui, Norio Itokawa, Michitaka Imai, Kouji Joko, Yoichi Hiasa, Kojiro Michitaka
Abstract
Regardless of past TKI therapy, therapeutic response and AEs after introducing LEN were similar. LEN may be an important treatment for the present unmet need regarding TKI treatment against u-HCC.
Related Papers
- → Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial(2018)350 cited
- → Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment(2017)66 cited
- → Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging(2019)24 cited
- → Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting(2021)7 cited
- → P-40 Lenvatinib versus sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study(2021)